Dr. Southern is a Staff Physician in the Respiratory Institute and Assistant Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He has a secondary appointment as an Associate Staff Scientist in the Lerner Research Institute Department of Pathobiology, where his research focus is Idiopathic Pulmonary Fibrosis (IPF). Dr. Southern explores how fibroblasts and myofibroblasts (the scar-producing cells in IPF) interact with lung tissue matrix to propagate fibrosis. He has identified that the molecular motor protein, non-muscle myosin II, is a critical molecule driving fibrosis, and is further characterizing the myosin II pathway in fibroblasts in order to identify novel targets to halt fibrosis in patients with IPF.
In addition to his research activities, Dr. Southern conducts an outpatient clinic where he cares for patients with interstitial lung disease and sarcoidosis, and he is a co-investigator on a number of clinical trials for patients with IPF. He serves as the physician leader for the Cleveland area Pulmonary Fibrosis Support Group.
Fellowship - Case Western Reserve University - University Hospitals of Cleveland
Pulmonary & Critical Care Medicine
Cleveland, OH USA
2012
Residency - Case Western Reserve University - University Hospitals of Cleveland
Internal Medicine
Cleveland, OH USA
2009
Medical Education - University of Alabama School of Medicine
Birmingham, AL USA
2003
Undergraduate - University of Alabama at Birmingham
Birmingham, AL USA
1996
View publications for Brian Southern, MD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Our education and training programs offer hands-on experience at one of the nationʼs top hospitals. Travel, publish in high impact journals and collaborate with investigators to solve real-world biomedical research questions.
Learn MoreCleveland Clinic study unveils mechanisms underlying fibrosis progression and promising treatment avenue.